Related references
Note: Only part of the references are listed.Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Paul W. Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Sex-based differences in heart failure across the ejection fraction spectrum: phenotyping, prognostic and therapeutic implications
D. Stolfo et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Trends in the Explanatory or Pragmatic Nature of Cardiovascular Clinical Trials Over 2 Decades
Nariman Sepehrvand et al.
JAMA CARDIOLOGY (2019)
Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum Phenotyping, and Prognostic and Therapeutic Implications
Davide Stolfo et al.
JACC-HEART FAILURE (2019)
Trends in Consent for Clinical Trials in Cardiovascular Disease
Louis A. Kerkhoff et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Enrollment in Heart Failure Clinical Trials: Insights Into Which Entry Criteria Exclude Patients
Arun Krishnamoorthy et al.
JOURNAL OF CARDIAC FAILURE (2015)
Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores
Joanne Simpson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51 043 patients from the Swedish Heart Failure Registry
Ulrik Sartipy et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies
Stuart J. Pocock et al.
EUROPEAN HEART JOURNAL (2013)
Patient- and Trial-Specific Barriers to Participation in Cardiovascular Randomized Clinical Trials
Seth S. Martin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Share Paper
